The DOI matches its Crossref record.
Viable Mouse Models of Acid β-Glucosidase Deficiency
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The pathology is primarily driven by reduced PSAP protein because homozygous Gba1D409H mice have only subtle phenotypes (43, 45).”
From Treatment of a genetic brain disease by CNS-wide microglia replacement (2022) · cites this paper as [45]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 41
- Blom, 1983, Gaucher disease–Norrbottnian type: neurodevelopmental, neurological, and neurophysiological aspects, Eur J Pediatr, 140, 316, 10.1007/BF00442672 · DOI
- Kolodny, 1982, Phenotypic manifestations of Gaucher disease: clinical features in 48 biochemically verified type 1 patients and comment on type 2 patients, Prog Clin Biol Res, 95, 33
- Volk, 1967, Infantile Gaucher's disease: electron microscopic and histochemical studies of a cerebral biopsy, J Neuropathol Exp Neurol, 26, 176
- Adachi, 1967, Fine structure of central nervous system in early infantile Gaucher's disease, Arch Pathol (Chicago), 83, 513
- Charrow, 2000, The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease, Arch Intern Med, 160, 2835, 10.1001/archinte.160.18.2835 · DOI
- Sibille, 1993, Phenotype/genotype correlations in Gaucher disease type I: clinical and therapeutic implications, Am J Hum Genet, 52, 1094
- Abrahamov, 1995, Gaucher's disease variant characterised by progressive calcification of heart valves and unique genotype, Lancet, 346, 1000, 10.1016/S0140-6736(95)91688-1 · DOI
- Theophilus, 1989, Gaucher disease: molecular heterogeneity and phenotype-genotype correlations, Am J Hum Genet, 45, 212
- Theophilus, 1989, Comparison of RNase A, a chemical cleavage and GC-clamped denaturing gradient gel electrophoresis for the detection of mutations in exon 9 of the human acid β-glucosidase gene, Nucleic Acids Res, 17, 7707, 10.1093/nar/17.19.7707 · DOI
- Grace, 1994, Analysis of human acid β-glucosidase by site-directed mutagenesis and heterologous expression, J Biol Chem, 269, 2283, 10.1016/S0021-9258(17)42166-1 · DOI
- Sidransky, 1996, The clinical, molecular, and pathological characterisation of a family with two cases of lethal perinatal type 2 Gaucher disease, J Med Genet, 33, 132, 10.1136/jmg.33.2.132 · DOI
- Finn, 2000, Severe type II Gaucher disease with ichthyosis, arthrogryposis, and neuronal apoptosis: molecular and pathological analyses, Am J Med Genet, 91, 222, 10.1002/(SICI)1096-8628(20000320)91:3<222::AID-AJMG13>3.0.CO;2-# · DOI
- Tayebi, 1997, Prenatal lethality of a homozygous null mutation in the human glucocerebrosidase gene, Am J Med Genet, 73, 41, 10.1002/(SICI)1096-8628(19971128)73:1<41::AID-AJMG9>3.0.CO;2-S · DOI
- Tybulewicz, 1992, Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene, Nature, 357, 407, 10.1038/357407a0 · DOI
- Liu, 1998, Mice with type 2 and 3 Gaucher disease point mutations generated by a single insertion mutagenesis procedure, Proc Natl Acad Sci USA, 95, 2503, 10.1073/pnas.95.5.2503 · DOI
- Kyle, 1990, Correction of murine mucopolysaccharidosis VII by a human β-glucuronidase transgene, Proc Natl Acad Sci USA, 87, 3914, 10.1073/pnas.87.10.3914 · DOI
- Vogler, 1990, A murine model of mucopolysaccharidosis VII: gross and microscopic findings in β-glucuronidase-deficient mice, Am J Pathol, 136, 207
- Sands, 1993, Treatment of murine mucopolysaccharidosis type VII by syngeneic bone marrow transplantation in neonates, Lab Invest, 68, 676
- Clarke, 1997, Murine mucopolysaccharidosis type I: targeted disruption of the murine α-L-iduronidase gene, Hum Mol Genet, 6, 503, 10.1093/hmg/6.4.503 · DOI
- de Geest, 2002, Systemic and neurologic abnormalities distinguish the lysosomal disorders sialidosis and galactosialidosis in mice, Hum Mol Genet, 11, 1455, 10.1093/hmg/11.12.1455 · DOI · Paper page
- Marathe, 2000, Hum Mol Genet, 9, 1967, 10.1093/hmg/9.13.1967 · DOI
- Li, 2002, Insertional mutagenesis of the mouse acid ceramidase gene leads to early embryonic lethality in homozygotes and progressive lipid storage disease in heterozygotes, Genomics, 79, 218, 10.1006/geno.2002.6686 · DOI
- Dahl, 1990, Gaucher disease type III (Norrbottnian type) is caused by a single mutation in exon 10 of the glucocerebrosidase gene, Am J Hum Genet, 47, 275
- Lewis, 1994, Mutation analysis of 28 Gaucher disease patients: the australasian experience, Am J Med Genet, 49, 218, 10.1002/ajmg.1320490212 · DOI
- O'Neill, 1989, Comparison of the chromosomal localization of murine and human glucocerebrosidase genes and of the deduced amino acid sequences, Proc Natl Acad Sci USA, 86, 5049, 10.1073/pnas.86.13.5049 · DOI
- Sabath, 1990, Glyceraldehyde-3-phosphate dehydrogenase mRNA is a major interleukin 2-induced transcript in a cloned T-helper lymphocyte, Gene, 91, 185, 10.1016/0378-1119(90)90087-8 · DOI
- Fabbro, 1987, Gaucher disease: genetic heterogeneity within and among the subtypes detected by immunoblotting, Am J Hum Genet, 40, 15
- O'Reilly, 1992
- Grabowski, 1986, Human acid β-glucosidase: use of conduritol B epoxide derivatives to investigate the catalytically active normal and Gaucher disease enzymes, J Biol Chem, 261, 8263, 10.1016/S0021-9258(19)83905-4 · DOI
- Fujita, 1996, Targeted disruption of the mouse sphingolipid activator protein gene: a complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids, Hum Mol Genet, 5, 711, 10.1093/hmg/5.6.711 · DOI
- Wells, 1963, The use of Sephadex for the removal of non-lipid contaminants from lipid extracts, Biochemistry, 2, 1259, 10.1021/bi00906a015 · DOI
- Dreyfus, 1997, Successive isolation and separation of the major lipid fractions including gangliosides from single biological samples, Anal Biochem, 249, 67, 10.1006/abio.1997.2143 · DOI
- Igisu, 1983, Abnormal accumulation of galactosylceramide in the kidney of twitcher mouse, Biochem Biophys Res Commun, 110, 940, 10.1016/0006-291X(83)91053-7 · DOI
- Daniels, 1982, Brain glucocerebrosidase in Gaucher's disease, Arch Neurol, 39, 550, 10.1001/archneur.1982.00510210020005 · DOI
- Mizukami, 2002, Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage, J Clin Invest, 109, 1215, 10.1172/JCI0214530 · DOI
- Sauer, 1998, Inducible gene targeting in mice using the Cre/lox system, Methods, 14, 381, 10.1006/meth.1998.0593 · DOI
- Conzelmann, 1983, Partial enzyme deficiencies: residual activities and the development of neurological disorders, Dev Neurosci, 6, 58, 10.1159/000112332 · DOI
- Svennerholm, 1982, Chemical differentiation of the Gaucher subtypes, Prog Clin Biol Res, 95, 231
- Conradi, 1984, Neuropathology of the Norrbottnian type of Gaucher disease: morphological and biochemical studies, Acta Neuropathol (Berl), 65, 99, 10.1007/BF00690463 · DOI
- Pasmanik-Chor, 1996, The glucocerebrosidase D409H mutation in Gaucher disease, Biochem Mol Med, 59, 125, 10.1006/bmme.1996.0077 · DOI
- Latham, 1991, Heterogeneity of mutations in the acid β-glucosidase gene of Gaucher disease patients, DNA Cell Biol, 10, 15, 10.1089/dna.1991.10.15 · DOI
Cited by
Treatment of a genetic brain disease by CNS-wide microglia replacement
Shibuya, Y., Kumar, K. K., Mader, M. M.-D., Yoo, Y., Ayala, L. A., Zhou, M., Mohr, M. A., Neumayer, G., Kumar, I., Yamamoto, R., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl9945 · Cited by 126
Genetic Defects and Pro-inflammatory Cytokines in Parkinson's Disease
Magnusen, A. F., Hatton, S. L., Rani, R., & Pandey, M. K. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.636139 · Cited by 47
Metadata
- Authors
- Xu, Y.-H., Quinn, B., Witte, D., & Grabowski, G. A.
- Venue
- The American Journal of Pathology
- Publisher
- Elsevier BV
- Published
- 2003-11
- Volume
- 163
- Issue
- 5
- Pages
- 2093-2101
- ISSN
- 0002-9440
- Cited by
- 170
- References
- 0
- Language
- en
- Funders
- National Institutes of Health (DK 36729)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review